Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Genzyme Receives Company Award

Published: Thursday, February 28, 2013
Last Updated: Thursday, February 28, 2013
Bookmark and Share
Genzyme, announced that it has received a Company Award from EURORDIS, the largest European patient organization in the field of rare diseases.

The EURORDIS Company Award recognizes the outstanding accomplishments of companies dedicated to rare diseases. Genzyme was honored for pioneering the development and delivery of therapies for rare diseases, its longstanding support of patient organizations, including EURORDIS, as well as initiatives to increase patient access to Genzyme treatments.

EURORDIS Award recipients are selected by the EURORDIS Board of Directors, from over 100 nominations received from EURORDIS members (rare disease patient advocacy groups from all Europe), volunteers and staff, with the aim of promoting leadership and excellence for people living with rare diseases. Genzyme’s Senior Vice President of Rare Diseases in Europe, Hilde Furberg, accepted the award yesterday during the EURORDIS Black Pearl Gala Dinner in Brussels as EURORDIS began its activities to recognize International Rare Disease Day.

“Genzyme has been partnering with patient advocacy organizations globally from our earliest days to be sure the community’s needs and perspectives are always represented within our organization, and the contributions of these organizations remain central to Genzyme and our ability to bring therapies to patients,” said Genzyme’s Head of Rare Diseases, Rogerio Vivaldi, MD. “As we approach Rare Disease Day, a day made possible because of EURORDIS, Genzyme wants to thank all of the patient organizations and communities who work daily to improve the lives of patients living with rare diseases. Their pioneering spirit will continue to inspire Genzyme.”

Yann Le Cam, Chief Executive Officer of EURORDIS, said, "We are honored to acknowledge the commitment and achievements of this year’s recipients of the EURORDIS Awards on the occasion of Rare Disease Day 2013. Each of this year’s ten awardees contributes in their own unique way toward fostering the goals of cooperation embodied in this year’s Rare Disease Day slogan: ‘Rare Disorders without Borders.’ We are proud that the rare disease community is becoming a model for multi-stakeholder partnership and international collaboration as well as for solidarity and unity throughout Europe.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Genzyme, Ablynx Launch MS Collaboration
Genzyme has agreed to use Ablynx's therapeutic proteins to carry out in vitro and in vivo research on multiple sclerosis models, then develop therapies against the disease.
Tuesday, May 19, 2015
Genzyme and Alnylam Expand Collaboration
Genzyme and Alnylam Pharmaceuticals have significantly expanded their strategic agreement to develop and commercialize treatments for rare genetic diseases.
Tuesday, January 14, 2014
Genzyme Celebrates Fifth Annual World MS Day
Company’s long-term commitment to MS extends beyond innovative therapies to new programs that address global needs of community.
Thursday, May 30, 2013
Genzyme’s Head of Rare Diseases Honored by the Genetic Disease Foundation
Rogerio Vivaldi MD receives Industry Person of the Year.
Tuesday, March 05, 2013
Genzyme’s LEMTRADA™ Application for MS Accepted for Review by the FDA
Genzyme also reports very encouraging early launch indicators for AUBAGIO® (teriflunomide) in U.S.
Tuesday, January 29, 2013
Genzyme Submits Applications to FDA and EMA for Approval of LEMTRADA™ for Multiple Sclerosis
Genzyme is developing LEMTRADA in MS in collaboration with Bayer HealthCare.
Wednesday, June 13, 2012
Genzyme's Biologics Support Center Achieves LEED Gold Rating for Environmentally Responsible Design
Site is Genzyme's tenth LEED-certified Green Building.
Friday, April 20, 2012
Genzyme and Veracyte Announce Global Co-Promotion Agreement
The companies announced the partnership will provide personalized and comprehensive solution for thyroid patients.
Monday, January 23, 2012
FDA Advisory Panel to Discuss Genzyme’s Myozyme BLA on Tuesday
Genzyme Corporation today announced that its U.S. Biologic License Application (BLA) for Myozyme® (alglucosidase alfa) produced at the 2000 L bioreactor scale will be discussed this Tuesday, October 21st, at a public meeting of the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee in Silver Spring, Maryland.
Monday, October 20, 2008
Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
Gene Therapy for Metabolic Liver Diseases
Researchers have tested gene therapy in pigs from hereditary tyrosinemia type 1, with corrected liver cells being transplanted into the diseased liver.
New Medication Shows Promise Against Liver Fibrosis in Animal Studies
Liver fibrosis is a gradual scarring of the liver that puts people at risk for progressive liver disease and liver failure.
Raw Eggs Deemed Safe to Eat
A report published today by the Advisory Committee on the Microbiological Safety of Food (ACMSF) into egg safety has shown a major reduction in the risk from salmonella in UK eggs.
Monitoring TTX Toxin in Shellfish
In a number of small studies, mussels and oysters from the eastern and northern part of the Oosterschelde in Holland were found to contain tetrodotoxin (TTX).
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Gene-Editing 'Toolbox' Targets Multiple Genes Simultaneously
Researchers have designed a system that modifies, or edits, multiple genes in a genome at once while minimising unintentional effects.
Detecting Alzheimer's with Smell Test
Odour identification test may offer low-cost alternative for predicting cognitive decline and detecting early-stage Alzheimer’s disease.
Antibody Drug Shows Promise in HIV Treatment
Researchers are a step closer to an alternative HIV treatment that has the potential for lasting effects and less frequent dosing.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!